Novel Metalloporphyrins and Related Metal Complexes for the Treatment of Oxidative Stress and Diseases with Oxidative Components

Web Published:


Princeton Invention # 99-1608


Researchers in the Chemistry Department at Princeton University have developed novel metalloporphyrins that offer new potential pharmaceuticals for the treatment of diseases such as diabetes, ischemia-reperfusion injury, stroke, inflammation, neurodegeneration, and sepsis in which active oxygen (ROS) and active nitrogen (RNS) species are thought to be involved in pathogenesis. These compounds have also shown to have protective effects against doxorubicin-induced cardiac dysfunction. The lead compound FP15 and series of analogs provide the opportunity for low dose, orally active therapeutics for diseases in areas of large unmet needs.


Successful drug candidates need to have a combination of characteristics such as high activity, low toxicity, bioavailability, stability and ease of synthesis and characterization. The approach used by Princeton researchers allows for short, efficient synthesis of highly active compounds that can be targeted to specific tissue and flexibly adapted to numerous applications. With over two decades of experience in the chemical synthesis and characterization of such compounds, the novelty of these agents lies in the particular combination of structural parts that retain activity while building in the other desired synthetic, characterization, biological and pharmacokinetic attributes.


Published studies using the lead compound, FP15 have demonstrated efficacy in a number of animal models (as cited below). Additionally orally administered FP15 is effective in correcting a number of pathological conditions associated with oxidative stress, including early diabetic neuropathy, in much lower doses than typical superoxide dismutase mimetics which strongly suggests the major contribution of peroxynitrite to oxidative/nitrosative stress-induced cytotoxic effects in diabetic peripheral nerve.



Princeton is currently seeking industrial collaborators to commercialize this technology. Patent protection is pending.


For more information on Princeton University Invention # 99-1608, please contact:



                        Laurie Tzodikov

                        Office of Technology Licensing and Intellectual Property

                        Princeton University

                        4 New South Building

                        Princeton, NJ 08544-0036

                        (609) 258-7256

                        (609) 258-1159 fax



Patent Information:
For Information, Contact:
Laurie Tzodikov
Licensing Associates
Princeton University
John (Jay) Groves
Suzanne Moeller